Hepatitis C virus non-structural NS3/4A fusion gene
Disclosed herein is the discovery of a novel hepatitis C virus (HCV) isolated from a human patient. Embodiments of the invention include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as, methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.
1. A composition comprising a purified or isolated nucleic acid that comprises at least 100 consecutive nucleotides of SEQ. ID. No. 1 or the complement thereof, wherein said at least 100 consecutive nucleotide encodes a polypeptide comprising a NS3 domain of a fragment thereof.
2. The composition of claim 1 , wherein said nucleic acid comprises at least 200 consecutive nucleotides of SEQ. ID. No. 1.
3. The composition of claim 1 , wherein said nucleic acid comprises at least 500 consecutive nucleotides of SEQ. ID. No. 1.
4. The composition of claim 1 , wherein said nucleic acid comprises at least 1000 consecutive nucleotides of SEQ. ID. No. 1.
5. The composition of claim 1 , wherein said nucleic acid comprises a mutation that inhibits proteolytic cleavage of NS3 and NS4A.
6. The composition of claim 2 , wherein said nucleic acid comprises a mutation that inhibits proteolytic cleavage of NS3 and NS4A.
7. The composition of claim 3 , wherein said nucleic acid comprises a mutation that inhibits proteolytic cleavage of NS3 and NS4A.
8. The composition of claim 4 , wherein said nucleic acid comprises a mutation that inhibits proteolytic cleavage of NS3 and NS4A.
9. The composition of claim 1 , wherein said nucleic acid encodes a polypeptide lacking a proteolytic cleavage site that inhibits proteolytic cleavage of NS3 and NS4A.
10. The composition of claim 1 , comprising a vector that comprises said nucleic acid.
11. The composition of claim 2 , comprising a vector that comprises said nucleic acid.
12. The composition of claim 3 , comprising a vector that comprises said nucleic acid.
13. The composition of claim 4 , comprising a vector that comprises said nucleic acid.
14. The composition of claim 5 , comprising a vector that comprises said nucleic acid.
15. The composition of claim 6 , comprising a vector that comprises said nucleic acid.
16. The composition of claim 7 , comprising a vector that comprises said nucleic acid.
17. The composition of claim 8 , comprising a vector that comprises said nucleic acid.
18. The composition of claim 9 , comprising a vector that comprises said nucleic acid.
19. The composition of claim 1 , further comprising an adjuvant.
20. The composition of claim 2 , further comprising an adjuvant.
21. The composition of claim 3 , further comprising an adjuvant.
22. The composition of claim 4 , further comprising an adjuvant.
23. The composition of claim 5 , further comprising an adjuvant.
24. The composition of claim 6 , further comprising an adjuvant.
25. The composition of claim 7 , further comprising an adjuvant.
26. The composition of claim 8 , further comprising an adjuvant.
27. The composition of claim 9 , further comprising an adjuvant.
28. The composition of claim 1 , further comprising ribavirin.
29. The composition of claim 2 , further comprising ribavirin.
30. The composition of claim 3 , further comprising ribavirin.
31. The composition of claim 4 , further comprising ribavirin.
32. The composition of claim 5 , further comprising ribavirin.
33. The composition of claim 6 , further comprising ribavirin.
34. The composition of claim 7 , further comprising ribavirin.
35. The composition of claim 8 , further comprising ribavirin.
36. The composition of claim 9 , further comprising ribavirin.
37. The composition of claim 1 , wherein said composition is formulated for use with an electroporation device.
38. The composition of claim 1 , wherein said composition is formulated for use with an injection device.
39. The composition of claim 38 , wherein said injection device is a needleless injection device.
40. The composition of claim 2 , wherein said composition is formulated for use with an electroporation device.
41. The composition of claim 2 , wherein said composition is formulated for use with an injection device.
42. The composition of claim 41 , wherein said injection device is a needleless injection device.
43. The composition of claim 3 , wherein said composition is formulated for use with an electroporation device.
44. The composition of claim 3 , wherein said composition is formulated for use with an injection device.
45. The composition of claim 44 , wherein said injection device is a needleless injection device.
46. The composition of claim 4 , wherein said composition is formulated for use with an electroporation device.
47. The composition of claim 4 , wherein said composition is formulated for use with an injection device.
48. The composition of claim 47 , wherein said injection device is a needleless injection device.
49. The composition of claim 5 , wherein said composition is formulated for use with an electroporation device.
50. The composition of claim 5 , wherein said composition is formulated for use with an injection device.
51. The composition of claim 50 , wherein said injection device is a needleless injection device.
52. The composition of claim 6 , wherein said composition is formulated for use with an electroporation device.
53. The composition of claim 6 , wherein said composition is formulated for use with an injection device.
54. The composition of claim 53 , wherein said injection device is a needleless injection device.
55. The composition of claim 7 , wherein said composition is formulated for use with an electroporation device.
56. The composition of claim 7 , wherein said composition is formulated for use with an injection device.
57. The composition of claim 56 , wherein said injection device is a needleless injection device.
58. The composition of claim 8 , wherein said composition is formulated for use with an electroporation device.
59. The composition of claim 8 , wherein said composition is formulated for use with an injection device.
60. The composition of claim 59 , wherein said injection device is a needleless injection device.
61. The composition of claim 9 , wherein said composition is formulated for use with an electroporation device.
62. The composition of claim 9 , wherein said composition is formulated for use with an injection device.
63. The composition of claim 62 , wherein said injection device is a needleless injection device.
64. A composition comprising a purified or isolated nucleic acid that comprises at least 100 consecutive nucleotides encoding a peptide sequence of SEQ. ID. NO: 2.
65. The composition of claim 1 , wherein said nucleic acid comprises at least 500 consecutive nucleotides encoding the peptide sequence of SEQ. ID. NO: 2.
66. The composition of claim 64 , further comprising an adjuvant.
67. The composition of claim 64 , further comprising ribavirin.
68. The composition of claim 64 , wherein said composition is formulated for use with an electroporation device.
69. The composition of claim 64 , wherein said composition is formulated for use with an injection device.
70. The composition of claim 69 , wherein said injection device is a needleless injection device.